Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

EF Hutton Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target

Author: Benzinga Newsdesk | August 30, 2024 03:10pm
EF Hutton analyst Jason Kolbert maintains Can Fite Biofarma (AMEX:CANF) with a Buy and maintains $10 price target.

Posted In: CANF

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist